Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel antagonists of MCHR-1 presented by sanofi-aventis

Aug. 31, 2010

Shionogi and LifeCycle end North American license agreement for Fenoglide

Aug. 31, 2010

Novel xanthine dehydrogenase/oxidase inhibitors show potent hypouricemic effects in vivo

Aug. 31, 2010

Representative of new class of SGLT2 inhibitors enters phase II development

Aug. 31, 2010

Schering presents new agonists of free fatty acid receptor 1

Aug. 30, 2010

Vitae Pharmaceuticals discloses novel 11beta-HSD1 inhibitors

Aug. 30, 2010

Exelixis discovers new inhibitors of ceramide glucosyltransferase

Aug. 30, 2010

Otsuka Pharmaceutical Factory claims new lipoprotein lipase-activating agents

Aug. 30, 2010

PSN-632408 stimulates replication of beta-cells in preclinical study

Aug. 30, 2010

Karo Bio reviews phase III eprotirome program in hypercholesterolemia

Aug. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...